Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH).
Thirty patients with BPH were randomized into two groups to receive Raveron and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron and placebo.
Bircan
K
K
Department of Urology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ozen
H A
HA
Ergen
A
A
Başar
I
I
Ozgür
S
S
Ilker
Y
Y
Karaağaoğlu
E
E
Remzi
D
D
D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014020:Tissue Extracts / Q000627:therapeutic use*; D014563:Urodynamics / Q000187:drug effects
D010919:Placebos; C012025:Robaveron; D014020:Tissue Extracts